adam feuerstein: AEGR knows that it has to hew close to high risk HoFH patients if it wants to get lomi approved. Any suggestion of population creep makes the risk-benefit argument more challenging.
adam feuerstein: so far, so good for AEGR
Comment From Take Take : ]
AGER defending its product very well... Nice still lots of dicussions to go...
Wednesday October 17, 2012 10:16 Take
10:16 adam feuerstein: agreed
adam feuerstein: AEGR's presentation was very well done.
adam feuerstein: AEGR and its docs stress that hoFH definition is made on clinical parameters not on mutation of the LDL receptors. IF thats true, patients numbers will be higher.